GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)
- Previous Close
2,077.25 - Open
2,078.00 - Bid --
- Ask --
- Day's Range
2,041.00 - 2,114.00 - 52 Week Range
1,227.00 - 2,524.00 - Volume
190,240 - Avg. Volume
164,718 - Market Cap (intraday)
350.355B - Beta (5Y Monthly) 0.22
- PE Ratio (TTM)
66.29 - EPS (TTM)
31.16 - Earnings Date May 17, 2024
- Forward Dividend & Yield 32.00 (1.54%)
- Ex-Dividend Date Jun 30, 2023
- 1y Target Est
2,011.00
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of Shingles and Post herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; TENOVATE and Flutivate for skin conditions to reduce inflammation; PHYSIOGEL for dry skin and dry skin associated with redness and itch; Zimig for fungal skin infections; COBADEX CZS, a multivitamin; and Supacef, a bactericidal cephalosporin antibiotic. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
india-pharma.gsk.com3,680
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: GLAXO.NS
Performance Overview: GLAXO.NS
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLAXO.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLAXO.NS
Valuation Measures
Market Cap
352.33B
Enterprise Value
335.33B
Trailing P/E
66.51
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.62
Price/Book (mrq)
22.86
Enterprise Value/Revenue
10.13
Enterprise Value/EBITDA
41.61
Financial Highlights
Profitability and Income Statement
Profit Margin
15.97%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
33.11B
Net Income Avi to Common (ttm)
5.29B
Diluted EPS (ttm)
31.16
Balance Sheet and Cash Flow
Total Cash (mrq)
16.05B
Total Debt/Equity (mrq)
1.39%
Levered Free Cash Flow (ttm)
--
Research Analysis: GLAXO.NS
Company Insights: GLAXO.NS
GLAXO.NS does not have Company Insights